{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T14:10:26Z","timestamp":1735308626393,"version":"3.32.0"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["PRA"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Introduction:<\/jats:title>\n<jats:p>Splenic marginal zone Lymphoma (SMZL) is a rare, chronic B\nlymphocyte proliferative disease. Generally, SMZL is accompanied by circulating atypical\nvillous lymphocytes, known as SMZL with villous lymphocytes. Rituximab is a chimeric\nmonoclonal antibody to CD20; recent but limited studies have confirmed its effectiveness\nin treating SMZL. Given the low incidence and selection of treatment, statistical comparisons\nof rituximab monotherapy with other available treatment options with the full range of\ndata from previous clinical studies remain sparse. Here, we report a case of SMZL with\nvillous lymphocytes treated by rituximab monotherapy, which is especially infrequently reported.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Case Report:<\/jats:title>\n<jats:p>A 63-year-old Chinese female was presented to the hospital with complaints of\nsplenomegaly and pain in the spleen area. Immunohistochemistry analysis was positive for IGH,\nIGK, and IGL clonal rearrangement. Villous lymphocytes were found in peripheral blood and\nbone marrow, along with further immunotyping results. The case was considered as SMZL with\nvillous lymphocytes. Based on the SMZLSG prognosis assessment, we applied rituximab monotherapy.\nAfter eight cycles of rituximab treatment, the patient\u2019s condition improved markedly,\nwith blood constituent and size of the spleen returning to normal levels, achieving complete response,\nwith no significant side effect observed.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion:<\/jats:title>\n<jats:p>The patient provides a typical SMZL with villous lymphocytes case treated with\nrituximab monotherapy. Currently, the main treatment options include splenectomy and rituximab.\nAfter synthesizing a series of current views, we put forward our opinion about the selection\nof therapy for SMZL patients in order to gain maximum benefits for patients in need of\ntreatment.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Our analysis found no statistically significant difference between rituximab monotherapy\nand rituximab combined with chemotherapy, while rituximab treatments resulted in better\ntherapeutic effects than chemotherapy. Rituximab monotherapy has favorable therapeutic\neffects and minor adverse effects (AEs) in treating SMZL.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0115748928247369231024112003","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T06:35:56Z","timestamp":1699598156000},"page":"121-130","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review"],"prefix":"10.2174","volume":"20","author":[{"given":"Rong-Yan","family":"Guan","sequence":"first","affiliation":[{"name":"Department of Hematology, Daqing Oilfield General Hospital, Daqing, Heilongjiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9837-9586","authenticated-orcid":true,"given":"Xing-Ru","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Clinical\nMedicine, School of Medicine, Shanghai Jiao Tong University, Shanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zou-Fang","family":"Huang","sequence":"additional","affiliation":[{"name":"Ganzhou Key Laboratory of Hematology,\nDepartment of Hematology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi,\n341000, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,\nShanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue-Hang","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University,\nShanghai, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shengli Oilfield Central Hospital, Dongying, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Wei","family":"Mou","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Shengli Oilfield Central Hospital, Shandong, Dongying, Shandong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","volume":"127","author":"Arcaini L.","year":"2016","unstructured":"Arcaini L.; Rossi D.; Paulli M.; Splenic marginal zone lymphoma: From genetics to management. Blood  2016,127(17),2072-2081","journal-title":"Blood"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.3109\/10428194.2012.743655","volume":"54","author":"Liu L.","year":"2013","unstructured":"Liu L.; Wang H.; Chen Y.; Rustveld L.; Liu G.; Du X.L.; Splenic marginal zone lymphoma: A population-based study on the 2001\u20132008 incidence and survival in the United States. Leuk Lymphoma  2013,54(7),1380-1386","journal-title":"Leuk Lymphoma"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1002\/cncr.33117","volume":"126","author":"Florindez J.A.","year":"2020","unstructured":"Florindez J.A.; Alderuccio J.P.; Reis I.M.; Lossos I.S.; Splenic marginal zone lymphoma: A US population\u2010based survival analysis (1999\u20102016). Cancer  2020,126(21),4706-4716","journal-title":"Cancer"},{"key":"ref=4","first-page":"83","volume":"102","author":"Sabattini E.","year":"2010","unstructured":"Sabattini E.; Bacci F.; Sagramoso C.; Pileri S.A.; WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: An overview. Pathologica  2010,102(3),83-87","journal-title":"Pathologica"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/sj.leu.2405068","volume":"22","author":"Matutes E.","year":"2008","unstructured":"Matutes E.; Oscier D.; Montalban C.; Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia  2008,22(3),487-495","journal-title":"Leukemia"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.clml.2014.07.002","volume":"15","author":"Tarella C.","year":"2015","unstructured":"Tarella C.; Arcaini L.; Baldini L.; Italian society of hematology, italian society of experimental hematology, and italian group for bone marrow transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clin Lymphoma Myeloma Leuk  2015,15(2),75-85","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.3109\/10428194.2013.861067","volume":"55","author":"Lenglet J.","year":"2014","unstructured":"Lenglet J.; Traull\u00e9 C.; Mounier N.; Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma  2014,55(8),1854-1860","journal-title":"Leuk Lymphoma"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1600-0609.2005.00426.x","volume":"75","author":"Iannitto E.","year":"2005","unstructured":"Iannitto E.; Minardi V.; Calvaruso G.; Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes. Eur J Haematol  2005,75(2),130-135","journal-title":"Eur J Haematol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/sj.leu.2403440","volume":"18","author":"Lefr\u00e8re F.","year":"2004","unstructured":"Lefr\u00e8re F.; L\u00e9vy V.; Fran\u00e7ois S.; Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: An update. Leukemia  2004,18(11),1924-1925","journal-title":"Leukemia"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/hon.717","volume":"21","author":"Riccioni R.","year":"2003","unstructured":"Riccioni R.; Caracciolo F.; Galimberti S.; Cecconi N.; Petrini M.; Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol  2003,21(4),163-168","journal-title":"Hematol Oncol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hon.820","volume":"25","author":"Kalpadakis C.","year":"2007","unstructured":"Kalpadakis C.; Pangalis G.A.; Dimopoulou M.N.; Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol  2007,25(3),127-131","journal-title":"Hematol Oncol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/hon.844","volume":"26","author":"Bennett M.","year":"2008","unstructured":"Bennett M.; Yegena S.; Dave H.P.; Schechter G.P.; Rituximab monotherapy is highly effective in splenic marginal zone lymphoma. Hematol Oncol  2008,26(2),114","journal-title":"Hematol Oncol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.3109\/10428194.2015.1029925","volume":"56","author":"Iannitto E.","year":"2015","unstructured":"Iannitto E.; Luminari S.; Tripodo C.; Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: A Fondazione Italiana Linfomi phase II study. Leuk Lymphoma  2015,56(12),3281-3287","journal-title":"Leuk Lymphoma"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12957-020-02030-3","volume":"18","author":"Zhang S.","year":"2020","unstructured":"Zhang S.; Xuan Z.; Zhang L.; Lu J.; Song P.; Zheng S.; Splenic marginal zone lymphoma: A case report and literature review. World J Surg Oncol  2020,18(1),259","journal-title":"World J Surg Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1111\/bjh.12011","volume":"159","author":"Montalb\u00e1n C.","year":"2012","unstructured":"Montalb\u00e1n C.; Abraira V.; Arcaini L.; Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases. Br J Haematol  2012,159(2),164-171","journal-title":"Br J Haematol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1002\/cncr.21931","volume":"107","author":"Tsimberidou A.M.","year":"2006","unstructured":"Tsimberidou A.M.; Catovsky D.; Schlette E.; Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer  2006,107(1),125-135","journal-title":"Cancer"},{"key":"ref=17","first-page":"856","volume":"90","author":"Bennett M.","year":"2005","unstructured":"Bennett M.; Sharma K.; Yegena S.; Gavish I.; Dave H.P.; Schechter G.P.; Rituximab monotherapy for splenic marginal zone lymphoma. Haematologica  2005,90(6),856-858","journal-title":"Haematologica"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","volume":"34","author":"Salles G.","year":"2017","unstructured":"Salles G.; Barrett M.; Fo\u00e0 R.; Rituximab in B-Cell hematologic malignancies: A review of 20 years of clinical experience. Adv Ther  2017,34(10),2232-2273","journal-title":"Adv Ther"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0065-2776(08)60876-7","volume":"52","author":"Banchereau J.","year":"1992","unstructured":"Banchereau J.; Rousset F.; Human B lymphocytes: Phenotype, proliferation, and differentiation. Adv Immunol  1992,52,125-262","journal-title":"Adv Immunol"},{"key":"ref=20a","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/nature04489","volume":"439","author":"Boross P.","year":"2006","unstructured":"Boross P.; Leusen J.H.; Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature  2006,439(70778),851-855","journal-title":"Nature"},{"key":"ref=20b","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1080\/10428190903128660","volume":"50","author":"Weng W.K.","year":"2009","unstructured":"Weng W.K.; Levy R.; Immunoglobulin G.; Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma  2009,50(9),1494-1500","journal-title":"Leuk Lymphoma"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","volume":"18","author":"Kalpadakis C.","year":"2013","unstructured":"Kalpadakis C.; Pangalis G.A.; Angelopoulou M.K.; Treatment of splenic marginal zone lymphoma with rituximab monotherapy: Progress report and comparison with splenectomy. Oncologist  2013,18(2),190-197","journal-title":"Oncologist"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1111\/bjh.12036","volume":"159","author":"Else M.","year":"2012","unstructured":"Else M.; Mar\u00edn-Niebla A.; de la Cruz F.; Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma. Br J Haematol  2012,159(3),322-328","journal-title":"Br J Haematol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/annonc\/mds643","volume":"24","author":"Dreyling M.","year":"2013","unstructured":"Dreyling M.; Thieblemont C.; Gallamini A.; ESMO Consensus conferences: Guidelines on malignant lymphoma. part 2: Marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol  2013,24(4),857-877","journal-title":"Ann Oncol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.3109\/10428194.2016.1157877","volume":"57","author":"Kalpadakis C.","year":"2016","unstructured":"Kalpadakis C.; Pangalis G.A.; Sachanas S.; No evidence of splenic disease in patients with splenic marginal zone lymphoma undergoing splenectomy for autoimmune hemolytic anemia after monotherapy with rituximab. Leuk Lymphoma  2016,57(11),2705-2708","journal-title":"Leuk Lymphoma"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.beha.2016.07.004","volume":"30","author":"Kalpadakis C.","year":"2017","unstructured":"Kalpadakis C.; Pangalis G.A.; Angelopoulou M.K.; Vassilakopoulos T.P.; Treatment of splenic marginal zone lymphoma. Best Pract Res Clin Haematol  2017,30(1-2),139-148","journal-title":"Best Pract Res Clin Haematol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/bjh.13320","volume":"169","author":"Xing K.H.","year":"2015","unstructured":"Xing K.H.; Kahlon A.; Skinnider B.F.; Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia. Br J Haematol  2015,169(4),520-527","journal-title":"Br J Haematol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1182\/blood.V84.9.3047.3047","volume":"84","author":"Pozzato G.","year":"1994","unstructured":"Pozzato G.; Mazzaro C.; Crovatto M.; Low-grade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood  1994,84(9),3047-3053","journal-title":"Blood"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMoa013376","volume":"347","author":"Hermine O.","year":"2002","unstructured":"Hermine O.; Lefr\u00e8re F.; Bronowicki J.P.; Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med  2002,347(2),89-94","journal-title":"N Engl J Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1002\/cncr.20596","volume":"101","author":"Iannitto E.","year":"2004","unstructured":"Iannitto E.; Ambrosetti A.; Ammatuna E.; Splenic marginal zone lymphoma with or without villous lymphocytes. Cancer  2004,101(9),2050-2057","journal-title":"Cancer"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","volume":"3","author":"Thieblemont C.","year":"2002","unstructured":"Thieblemont C.; Felman P.; Berger F.; Treatment of splenic marginal zone B-cell lymphoma: An analysis of 81 patients. Clin Lymphoma  2002,3(1),41-47","journal-title":"Clin Lymphoma"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/10428190009054887","volume":"40","year":"2000","unstructured":"Lefr\u00c8Re F, Hermine O, Fran\u00c7Ois S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma  2000,40(1-2),113-117","journal-title":"Leuk Lymphoma"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.leukres.2009.04.003","volume":"34","author":"Orciuolo E.","year":"2010","unstructured":"Orciuolo E.; Buda G.; Sordi E.; 2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. Leuk Res  2010,34(2),184-189","journal-title":"Leuk Res"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/sj.leu.2401710","volume":"14","author":"Lefr\u00e8re F.","year":"2000","unstructured":"Lefr\u00e8re F.; Hermine O.; Belanger C.; Fludarabine: An effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia  2000,14(4),573-575","journal-title":"Leukemia"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1093\/annonc\/mdt181","volume":"24","author":"Cervetti G.","year":"2013","unstructured":"Cervetti G.; Galimberti S.; Pelosini M.; Ghio F.; Cecconi N.; Petrini M.; Significant efficacy of 2-chlorodeoxyadenosine\u00b1 rituximab in the treatment of splenic marginal zone lymphoma (SMZL): Extended follow-up. Ann Oncol  2013,24(9),2434-2438","journal-title":"Ann Oncol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","volume":"100","author":"Chac\u00f3n J.I.","year":"2002","unstructured":"Chac\u00f3n J.I.; Mollejo M.; Mu\u00f1oz E.; Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood  2002,100(5),1648-1654","journal-title":"Blood"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1365-2141.1991.tb04417.x","volume":"78","author":"Mulligan S.P.","year":"1991","unstructured":"Mulligan S.P.; Matutes E.; Dearden C.; Catovsky D.; Splenic lymphoma with villous lymphocytes: Natural history and response to therapy in 50 cases. Br J Haematol  1991,78(2),206-209","journal-title":"Br J Haematol"}],"container-title":["Recent Patents on Anti-Cancer Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928247369231024112003","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/223096\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0115748928247369231024112003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T13:44:12Z","timestamp":1735307052000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/223096\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0115748928247369231024112003","relation":{},"ISSN":["1574-8928"],"issn-type":[{"type":"print","value":"1574-8928"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-03-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}